Experience of the Tocilizumab Application in Systemic Onset Juvenile Arthritis
https://doi.org/10.15690/vsp.v14i5.1443
Abstract
The article provides information on the unfavourable course of systemic onset juvenile arthritis, resistant to immunosuppressive therapy with methotrexate in combination with cyclosporine, and pulse therapy with methylprednisolone and methotrexate. We describe the successful use of genetically engineered biological drug tocilizumab in the patient with systemic onset juvenile arthritis. After the first injection, pain was already significantly reduced; after the second, fever was relieved and non-steroid anti-inflammatory drugs were cancelled; after the third, lymphadenopathy and splenomegaly disappeared and the child’s functional activity improved significantly. After 12 months of treatment, an inactive phase of the disease was achieved, the joints’ kinetics (with the exception of the right hip) were almost entirely restored and the patient’s quality of life had significantly improved. At the same time, metabolic disorders and changes in the cardiovascular system were reversed. This example demonstrated the high effectiveness of interleukin-6 antagonist tocilizumab in systemic arthritis, which allowed arresting joint affection as well as extra-articular manifestations of the disease, providing normal puberty, the restoration of growth and sexual development.
About the Authors
A. V. Krasnopol’skaja
Ogarev Mordovia State University, Saransk, Russian Federation
Russian Federation
Russian Federation
O. N. Soldatova
Ogarev Mordovia State University, Saransk, Russian Federation
Russian Federation
Russian Federation
E. S. Samoshkina
Ogarev Mordovia State University, Saransk, Russian Federation
Russian Federation
Russian Federation
N. V. Shekina
Republican Pediatric Hospital, Saransk, Russian Federation
Russian Federation
Russian Federation
L. A. Balykova
Ogarev Mordovia State University, Saransk, Russian Federation
Russian Federation
Russian Federation
References
1. Kahn P. Juvenile idiopathic arthritis: an update for the clinician. Bull NYU Hosp Jt Dis. 2012; 70 (3): 152–166.
2. Баранов А. А., Алексеева Е. И. Ювенильный артрит: клинические рекомендации для педиатров. Детская ревматология. М.: ПедиатрЪ. 2013. 120 с.
3. Gurion R. R., Lehman T. J. A., Moorthy L. N. Systemic arthritis in children: a review of clinical presentation and treatment. Int. J. Inflam. 2012; Article ID 271569-16.
4. Woerner A., von Scheven-Gete A., Cimaz R., Hofer M. Complica tions of systemic juvenile idiopathic arthritis: risk factors and management recommendations. Exp. Rev. Clin. Immunol. 2015; 11 (5): 575–588.
5. Mellins E. D., MacAubas A., Grom A. A. Pathogenesis of systemic juvenile idiopathic arthritis: some answers, more questions. Nat. Rev. Rheum. 2011; 7 (7): 416–426.
6. Sikora K. A., Grom A. A. Update on the pathogenesis and treatment of systemic idiopathic arthritis. Curr. Opin. Pediatr. 2011; 23 (6): 640–646.
7. Bruck N., Schnabel A., Hedrich C. M. Current understanding of the pathophysiology of systemic juvenile idiopathic arthritis (sJIA) and target-directed therapeutic approaches. Clin. Immunol. 2015; 159 (1): 72–83.
8. Shimizu M., Nakagishi Y., Yachie A. Distinct subsets of patients with systemic juvenile idiopathic arthritis based on their cytokine profiles. Cytokine. 2013; 61 (2): 345–348.
9. Cazzola M., Ponchio L., De Benedetti F., Ravelli A., Rosti V., Beguin Y. et al. Defective iron supply for erythropoiesis and adequate endogenous erythropoietin production in the anemia associated with systemic-onset juvenile chronic arthritis. Blood. 1996; 87: 4824–4830.
10. De Benedetti F., Massa M., Robbioni P., Ravelli A., Burgio G. R., Martini A. Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis. Arthritis Rheum. 1991; 34: 1158–1163.
11. Hartman J., Frishman W. H. Inflammation and atherosclerosis: a review of the role of interleukin-6 in the development of atherosclerosis and the potential for targeted drug therapy. Cardiol. Rev. 2014; 22 (3): 147–151.
12. Ringold S., Weiss P. F., Beukelman T. Update of the 2011 American College of Rheumatology Recommendations for the Treatment of Juvenile Idiopathic Arthritis: Recommendations for the Medical Therapy of Children With Systemic Juvenile Idiopathic Arthritis and Tuberculosis Screening Among Children Receiving Biologic Medications. Arthritis Care & Res. 2013; 65 (10): 1551–1563.
13. Vannucci G., Cantarini L., Giani T., Marrani E., Moretti D., Pagnini I., Simonini G., Cimaz R. Glucocorticoids in the management of systemic juvenile idiopathic arthritis. Paediatr Drugs. 2013; 15 (5): 343–349.
14. Валиева С. И., Алексеева Е. И., Акулова С. С., Бзарова Т. М., Денисова Р. В., Исаева К. Б., Слепцова Т. В., Митенко Е. В., Чистякова Е. Г., Фетисова А. Н., Семикина Е. Л. Эффективность и безопасность длительного применения ритуксимаба у пациентов с системным ювенильным идиопатическим артритом. Вопросы современной педиатрии. 2013; 12 (2): 89–100.
15. Pardeo M., Pires Marafon D., Insalaco A., Bracaglia C., Nicolai R., Messia V., De Benedetti F. Anakinra in Systemic Juvenile Idiopathic Arthritis: A Single-center Experience. J. Rheumatol. 2015; 42 (8): 1523–1527.
16. Yokota S., Tanaka T., Kishimoto T. Efficacy, safety and tolerability of tocilizumab in patients with systemic juvenile idiopathic arthritis. Ther. Adv. Musculoskelet. Dis. 2012; 4 (6): 387–397.
17. Alexeeva E., Denisova R., Valieva S., Bzarova T., Isayeva K., Sleptsova T., Mitenko E. Safety and efficacy of tocilizumab treatment in children with systemic onset of juvenile idiopathic arthritis. Pediatr. Rheumatol. Online J. 2011; 9 (Suppl. 1): 202.
18. Каледа М. И., Никишина И. П. Лечение системного варианта ювенильного идиопатического артрита с применением генно-инженерных биологических препаратов в клинической практике. Педиатрия. 2015; 2: 116–124.
19. Brunner H. I., Ruperto N., Zuber Z., Keane C., Harari O., Kenwright A., Lu P., Cuttica R., Keltsev V., Xavier R. M., Calvo I., Niki shina I., Rubio-Perez N., Alexeeva E., Chasnyk V., Horneff G., Opoka-Winiarska V., Quartier P., Silva C. A., Silverman E., Spin dler A., Baildam E., Gamir M. L., Martin A., Rietschel C., Siri D., Smolewska E., Lovell D., Martini A., De Benedetti F. for the Paediatric Rheuma tology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG). Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, doubleblind withdrawal trial. Ann. Rheum. Dis. 2015; 74 (6): 1110–1117.
20. Балыкова Л. А., Краснопольская А. В., Корнилова Т. И., Широкова А. А. Проблема метаболических нарушений при ювенильных артритах у детей, проживающих на территории Республики Мордовия. Научно-практическая ревматология. 2014; (52) 5: 572–577.
21. DeWitt E. M., Kimura Y., Beukelman T., Nigrovic P. A., Onel K., Prahalad S., Schneider R., Stoll M. L., Angeles-Han S., Milojevic D., Schikler K. N., Vehe R. K., Weiss J. E., Weiss P., Ilowite N. T., Wallace C. A. Juvenile Idiopathic Arthritis Disease-specific Research Committee of Child-hood Arthritis Rheumatology and Research Alliance. Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis. Arthritis Care Res. (Hoboken). 2012; 64 (7): 1001–1010.
22. De Benedetti F., Brunner H. I., Ruperto N., Kenwright A., Wright S., Calvo I., Cuttica R., Ravelli A., Schneider R., Woo P., Wouters C., Xavier R., Zemel L., Baildam E., Burgos-Vargas R., Dolezalova P., Garay S. M., Merino R., Joos R., Grom A., Wulffraat N., Zuber Z., Zulian F., Lovell D., Martini A. PRINTO; PRCSG. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N. Engl. J. Med. 2012; 367: 2385–2395.
23. Alexeeva E., Denisova R., Valieva S., Bzarova T., Isayeva K., Sleptsova T., Chistyakova E., Fetisova A., Lomakina O. Effects of antirheumatic treatment with tocilizumab on longitudinal growth in children with juvenile idiopathic arthritis. Pediatr. Rheumatol. Online J. 2014; 12 (Suppl. 1): 62.
Review
For citations:
Krasnopol’skaja A.V., Soldatova O.N., Samoshkina E.S., Shekina N.V., Balykova L.A. Experience of the Tocilizumab Application in Systemic Onset Juvenile Arthritis. Current Pediatrics. 2015;14(5):579-585. (In Russ.) https://doi.org/10.15690/vsp.v14i5.1443
Views:
948
Email this article 
